DONALDSON-COMPANY
10.3.2020 13:02:17 CET | Business Wire | Press release
Donaldson Company, Inc. (NYSE: DCI), a leading worldwide manufacturer of filtration systems and solutions, today announced the expansion of the Donaldson iCue™ connected filtration service to Europe. The service monitors industrial dust collectors in real time to help facility teams improve dust collection management.
Early adopters of the iCue service, which was launched in September 2019 in North America, have reported benefits in three main categories:
- Reduced downtime for dust collection equipment and associated production lines,
- Lower maintenance costs for labor and parts, including longer filter replacement intervals, and
- Better management of dust collector tasks and compliance reporting data.
Based on research Donaldson has performed, 65 percent of surveyed facilities reported they would experience production downtime if their collector failed due to maintenance oversights. “Dust collection systems play an important role in helping manage airborne contaminants and emissions,” said Bart Robbeets, Sales Director of Industrial Air Filtration – After Market of Donaldson Europe & Middle East. “The iCue service provides real-time insights that can help facility teams troubleshoot issues earlier and keep a collector up and running. This added intelligence helps our customers drive efficiency, reduce costs, and improve their production uptime.”
The iCue connected filtration service monitors key operating metrics on a dust collector, with additional sensors available to meet specific needs. Users have access to service features that include:
- Real-time alerts e-mailed directly to facility teams for assessment and action,
- Easy-to-use dashboard detailing all dust collectors on the service,
- Automated historic performance reports on each dust collector, and
- Live customer success team for assistance.
“Facility managers tell us that actively monitoring their dust collectors’ performance is a challenge, in terms of both time and technical knowledge,” said Wade Wessels, Global Director of Connected Solutions with Donaldson. “Our iCue service automates monitoring and provides simple, actionable data that helps our customers manage their equipment with confidence and ease.”
The compact iCue device and wireless connection is simple to install, requires no IT integration with an internal automation network, and is compatible with major dust collector brands. An annual subscription includes hardware, automated reports, real-time maintenance alerts, and an online interface for more detailed analysis.
Learn more about the Donaldson iCue connected filtration service at Donaldson.com/ConnectedSolutions , email connectedsolutions-emea@donaldson.com , or phone at +1 833-898-5996.
About Donaldson Company
Founded in 1915, Donaldson Company is a global leader in the filtration industry with sales, manufacturing and distribution locations around the world. Donaldson’s innovative filtration technologies are designed to solve complex filtration challenges and enhance customers’ equipment performance.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200310005300/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom